Your post-surgery pain is this San Francisco drugmaker's gain and opiod users may benefit, too

Six years after starting its first clinical trial, a small San Francisco company hopes that moving its pain treatment into a late-stage trial will generate a fundraising buzz but no excitement for pain-drug addicts. Adynxx Inc. said Thursday that its signature drug — once called AYX-1 but now dubbed brivoligide — showed in the last of three mid-stage trials that it blocked pain long term for patients exiting single-knee replacement surgery. What's more, the company said, patients with a lower…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news